

Visit Evaluation (Adult)

Patient ID	_ ID
Date of Evaluation:	DOEDATE

Protocol timepoint (see codes): TMPT

Last protocol visit (mm/dd/yy): LVM / LVD / LVY

SECTION I:	ADVERSE	FFFFCTS
SECTION I.	ADVLINGE	LIILGIO

	CTION I: ADVERS									
1. I	las the patient had	any of the following	ng signs, symp	otoms, o	or side effect	ts since the last pr	otocol vi	sit:		
			<u>Yes</u>	<u>No</u>				<u>Yes</u>	<u>No</u>	
а	. Fatigue FATIG				I. Joint a	aches JOINT				
b	. Trouble sleeping	TSLP			m. Diarrh	ea DIARR				
С	. Headache HEAD	DACH			n. Vomit	ing VOMIT				
d	. Dizziness DIZZ				o. Upset	stomach USTON	1			
е	. Depression DEP	RESS			p. Muscl	e pain MUSPN				
f.	Weight loss (unin	tentional) WGTLC	oss 🗆		q. Rash	RASH				
g	. Decreased appet	ite DAPP			r. Skin i	rritation SKIN				
h	. Vision problems	VISION			s. Cold/F	Flu-like symptoms	FLU			
i.	Nausea NAUS				t. Hair lo	oss HAIR				
j.	Upper abdominal	pain ADPAIN			u. Other	SYMOTH				
k	. Breathing probler	ns BREATH			If yes,	specify: SYMOTI	HS			
(adverse event), sind Yes (Complete a No	•		complete	e the MedWa	atch form too)				
SE	CTION II: CONCO	MITANT MEDICA	TIONS							
	Has there been any			iption m	edications s	ince the last proto	col visit?	CON	/IED	
[□ Yes □ No	If Yes, update the	e Concomitant	Medica	ition Log					
2. I	s the patient curren	tly taking any herbs	s, "natural" or I	nerbal m	nedications?	MEDHERB □ Ye	es 🗆 No	□ Unl	known	I
	3. Is the patient currently taking vitamins or minerals? MEDVIT □ Yes □ No □ Unknown If Yes, <i>(check all that apply)</i>									
	☐ Multi-vitan VITMULT	nın ⊔ Vitamın D VITD	☐ Vitamin E			Iron □ Calcium TFE VITCA		ther OTH		
4. I	s the patient curren	tly taking any antiv	iral therapy for			nan study drug)? T			□ No	
If Yes, record all treatments										
	Antiviral Therapy		Date Stopped		Currently]				
-	(see codes)	(mm/dd/yy)	(mm/dd/yy)		n Therapy					
-	TXB1	TXB1BM/D/Y TXB2BM/D/Y	TXB1EM/D/Y		TXB1CUR	1 = IFN	6 = Peg			
-	TXB2	TXB3BM/D/Y	TXB2EM/D/Y		TXB2CUR	2 = Entecavir	7 = Ter			
-	TXB3 TXB4	TXB3BM/D/Y	TXB3EM/D/Y		TXB3CUR TXB4CUR	3 = Telbivudine 4 = Lamivudine	8 = Em 9 = Tru	tricitabin vada	ie	
-	TXB5	TXB5BM/D/Y	TXB4EM/D/Y		TXB4CUR	5 = Adefovir	-3 = Unk			
	IVDO		I VDAEIAI\D\ I		VDOCOK	1				



Visit Evaluation (Adult)

Patient ID _	ID	
Date of Eva	luation: DOEDATE	
Protocol tim	epoint (see codes): TMPT	

SI	ECTION III: STUDY MEDICATION (weeks 8 through 52, do not complete for Cont	rol patients)
1.	Did patient return dispensed bottle of entecavir? ETVRET ☐ Yes ☐ No	Complete Study Drug Log
2.	Did patient return used vials of peginterferon? PEGRET ☐ Yes ☐ No ☐ N/A	weeks 8 through 52
3.	Did the patient return a completed diary? DIARY ☐ Yes ☐ No	
4.	Ask the patient the following questions:	
	"Many people don't take their medications perfectly all of the time."	
	a. Over the past 7 days, how many times did you miss taking your entecavir pill?	ETVMISS Unknown
	b. Last dose of entecavir taken prior to visit (mm/dd/yy): ETVM /ETVD /ETVY D] Unknown
	c. Over the past 4 weeks, how many times did you miss taking your peg-interferon	injection? □ Unknown PEGMISS
	d. Last dose of peginterferon taken prior to visit (mm/dd/yy): PEGM / PEGD / PE	GY □ Unknown
5.	Was there a prescribed change in dose (decrease or increase) since the last protoco	ol visit? □ Yes □ No DCFORM
		nfirm acceptable method of
6.	Was counseling on adherence provided during visit? MATI ☐ Yes ☐ No ☐ con	traception, when applicable
SI	Blood pressure: BPS / BPD mmHg	IMOIMOS
NI/	OTE: Patients meeting AASLD criteria for HCC surveillance should have follow-up im	eaging per standard of care
INV	OTE. Patients meeting ADED chiena for 1100 surveillance should have follow-up in	laging per standard of care.
	Were samples obtained at this visit?	☐ Immunology study IMM
	Data collector initials: DCID	

November 6, 2015 v1.1 VEIT (Adult) Page 2 of 2

Date data collection completed (mm/dd/yy): DCM / DCD / DCY